Skip to content

Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn’s Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials

Oct 2026 · BioDrugs · Vol 40, pp. 1041 - 1053 · 0 citations · 36 references
Medicine
View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.